Arbutus Biopharma Reports Robust Q1 with $169.7M Net Income from Moderna Settlement, Plans Shareholder Capital Return
ABUS sits 51% above its 52-week low of $2.94.
Summary
Arbutus Biopharma reported a significant financial turnaround in Q1 2026, driven by a $178.7 million payment from the Moderna patent settlement, leading to a net income of $169.7 million and plans for a shareholder capital return.
Key Events · Earnings and Guidance · ABUS
-
Strong Q1 Financial Performance
Reported a net income of $169.7 million for Q1 2026, a substantial improvement from a net loss of $(24.5) million in Q1 2025. Basic EPS was $0.88 and diluted EPS was $0.87.
-
Moderna Settlement Payment Recognized
Recognized $178.7 million in license revenue from Genevant, representing Arbutus's portion of the $950.0 million noncontingent Moderna patent settlement payment, expected by July 8, 2026.
-
Significant Liquidity Boost
Cash, cash equivalents, and marketable securities totaled $95.2 million as of March 31, 2026, supplemented by a $178.7 million license receivable from Genevant, significantly strengthening the balance sheet.
-
Planned Shareholder Capital Return
The company is evaluating a return of capital to shareholders in Q3 2026, following the receipt of its portion of the Moderna settlement payment.
Analysis · ABUS · Life Sciences
Arbutus Biopharma's Q1 2026 results mark a significant financial turnaround, primarily driven by the $178.7 million noncontingent payment from the Moderna patent settlement. This influx of funds has dramatically improved the company's liquidity, boosting total current assets to $277.0 million and resulting in a net income of $169.7 million, a stark contrast to the loss in the prior year. The company's plan to return capital to shareholders in Q3 2026, following the receipt of the settlement payment, is a strong positive signal for investors. Additionally, the FDA's Fast Track designation for imdusiran and the ongoing Pfizer/BioNTech litigation with a favorable claim construction ruling provide further positive momentum, outweighing the negative impact of a European patent revocation which the company plans to appeal.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABUS was trading at $4.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $848.8M. The 52-week trading range was $2.94 to $5.10. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.